Blood Biomarker in Early Parkinson's Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

65 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-01-22

Study Completion Date

2019-01-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Currently, there are no cures or disease modifying therapies for Parkinson's disease (PD). This is partially due to the inability to detect the disease before it has progressed to a stage where there are clinical manifestations. The identification and validation of high throughput biomarkers to measure disease progression (as well as identify pre-clinical disease onset) is critical to the development of disease-modifying or even preventative therapies. In this study, we are testing a blood biomarker for PD. Several detection parameters will be assessed through enrollment of Parkinson's patients and age matched healthy volunteers over 50 years of age to learn more about the analytical process and biological variability.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Neuroplasticity in Parkinson's Disease

NCT05286736

Parkinson Parkinson Disease

RECRUITING

Development of Imaging, Clinical and Biochemical Bio-Markers for Parkinson's Disease

NCT00315250

Parkinson's Disease Parkinsonian Syndrome

COMPLETED PHASE2

Identification of a Biomarker Predictive of Evolution of Parkinson Disease

NCT03230526

Parkinson Disease

ACTIVE_NOT_RECRUITING PHASE2

Study of Individuals With Parkinson's Symptoms But in Whom There is Diagnostic Uncertainty

NCT00129675

Parkinsonian Syndrome

COMPLETED PHASE2

A Study Evaluating Potential Screening Tools for Detecting Parkinson Disease

NCT00387075

Parkinson Disease

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy Volunteers

No interventions assigned to this group

Parkinson's Disease

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Age matched to PD patient Parkinson's Disease Patients:

* 50 years and older
* PD patient who is seen at the Duke Movement Disorders Center
* Early PD diagnosis (Hoehn and Yahr scale ≤ 3)
* Non-smoking
* No cancer treatment in the last 5 years
* Able to read and speak English

Healthy Control Participants:

* 50 years and older
* Non-smoking
* No cancer treatment in the last 5 years
* Able to read and speak English

Exclusion Criteria

Parkinson's Disease Patients:

* Known additional neurological disease
* Clinical trial intervention within the last 6 months

Healthy Control Participants:

* Neurological degenerative diseases (such as Parkinson's, Alzheimer's or Huntington's)
* Clinical trial intervention within the last 6 months

Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes